MedPath

Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure

Not Applicable
Terminated
Conditions
Acute Respiratory Failure
Registration Number
NCT01243918
Lead Sponsor
Nantes University Hospital
Brief Summary

The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation).12 immunocompetent patients will compare the successive use of oxygen therapy delivery systems Optiflow®/Ospal® and 12 immunodeficient patients will compare the successive use of systems Optiflow®/Non invasive ventilation.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Patient hospitalized in the intensive care unit of Nantes University Hospital
  • Signed informed consent
  • Patient with not hypercapnic acute hypoxemic respiratory failure
  • Immunocompetent and immunodeficient patient
Exclusion Criteria
  • Age < 18 years
  • Pregnancy
  • Contra-indication to non invasive ventilation
  • Allergy to xylocaine
  • Coagulation troubles
  • Tracheotomized patient
  • Urgent indication to intubation
  • Hypercapnic acute respiratory failure
  • Acute pulmonary edema
  • Face or nose malformation

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Calcul of the ratio PaO2/FiO2one hour after each system used

The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation) by calculating the ratio PaO2/FiO2

Secondary Outcome Measures
NameTimeMethod
number of participants with adverse events

The secondary outcomes are to understand the mechanisms of action of Optiflow system and to evaluate the tolerance of this system:

* number of adverse events: respiratory events, trophic troubles, subjective events (comfort, dryness of mucous membranes, gastric distension, preferred system), serious hemodynamic and cardiovascular events

* impact on work of breathing: measure of respiratory frequency and blood gas

* measure of positive and expiratory pressure

measure of respiratory frequency and blood gas

The secondary outcomes are to understand the mechanisms of action of Optiflow system and to evaluate the tolerance of this system:

* number of adverse events: respiratory events, trophic troubles, subjective events (comfort, dryness of mucous membranes, gastric distension, preferred system), serious hemodynamic and cardiovascular events

* impact on work of breathing: measure of respiratory frequency and blood gas

* measure of positive and expiratory pressure

measure of positive and expiratory pressure

The secondary outcomes are to understand the mechanisms of action of Optiflow system and to evaluate the tolerance of this system:

* number of adverse events: respiratory events, trophic troubles, subjective events (comfort, dryness of mucous membranes, gastric distension, preferred system), serious hemodynamic and cardiovascular events

* impact on work of breathing: measure of respiratory frequency and blood gas

* measure of positive and expiratory pressure

Trial Locations

Locations (1)

Nantes University Hospital

🇫🇷

Nantes, France

Nantes University Hospital
🇫🇷Nantes, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.